Compare NAII & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAII | ICCC |
|---|---|---|
| Founded | 1980 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 93.1M |
| IPO Year | 1995 | 1995 |
| Metric | NAII | ICCC |
|---|---|---|
| Price | $2.00 | $9.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 18.3K | 16.2K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ 0.41 |
| Revenue | ★ $132,437,000.00 | $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $23.37 |
| Revenue Growth | 8.60 | ★ 51.64 |
| 52 Week Low | $1.94 | $4.52 |
| 52 Week High | $4.96 | $12.10 |
| Indicator | NAII | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 38.69 | 34.65 |
| Support Level | N/A | $9.55 |
| Resistance Level | $2.49 | $10.75 |
| Average True Range (ATR) | 0.12 | 0.24 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 15.26 | 9.53 |
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products, to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segments. The company derives the majority of revenue from Private-Label Contract Manufacturing, which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.